{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-001163","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.181127+00:00","generated_at":"2026-06-07T00:31:00.382700+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Esperion provides FY2024 operating expense guidance of $225M-$245M","bullets":["R&D expenses expected $45M-$55M for FY2024.","SG&A expenses expected $180M-$190M for FY2024.","Total operating expenses guided at $225M-$245M.","Guidance announced at 42nd Annual J.P. Morgan Healthcare Conference on Jan 10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-001163","json":"https://secwatch.observer/filing/0001628280-24-001163.json","markdown":"https://secwatch.observer/filing/0001628280-24-001163.md","text":"https://secwatch.observer/filing/0001628280-24-001163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/0001628280-24-001163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/espr-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:31:00.382700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e3cdfba3023ac80d8991b88cf4f541c27fbc8a3","claim":"Esperion Therapeutics, Inc. updated its the fiscal year ending December 31, 2024 guidance (initiated).","evidence_excerpt":"Esperion Therapeutics, Inc. (the “Company”) announced in its management presentation at the 42 nd Annual J.P. Morgan Healthcare Conference the following financial guidance for the fiscal year ending December 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/0001628280-24-001163-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ending December 31, 2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}